（来源：E药资本界） 2025年，中国医药健康产业正式迈入"创新深化+全球突围"双轮驱动的关键阶段。以小核酸、 PROTAC、CGT为代表的新兴疗法从临床验证加速迈向商业化兑现，ADC、双抗、TCE等前沿技术引领 创新药疗法升级；国产高端医疗设备与外周介入器械在中高端市场实现关键突破，国产替代进程持续提 速。 产业变革浪潮中，头部券商的深度研判成为穿透行业迷雾、把握核心机遇的重要指引。 2025年度中国券商十大医药技术研报汇聚来自华福证券、西南证券、国金证券、中信建投证券、国盛证 券、兴业证券、天风证券（维权）、平安证券、开源证券、东吴证券医药首席分析师精选的重磅报告， 覆盖技术迭代、产业趋势、全球化布局等核心议题。 这些报告不仅解码了技术突破的核心逻辑与商业化落地的关键节点，更精准捕捉了行业价值重构的新范 式，为产业从业者、投资者及行业观察者提供了兼具深度与前瞻性的权威参考。 接下来，让我们聚焦十大券商研报的核心精华，共探医药产业创新与增长的核心密码。 01 华福证券研究所副所长、医药首席分析师陈铁林 《小核酸行业深度：技术平台和适应症不断验证，迎来销售和临床密集兑现期》 ▲图为华福证券研究所副所长、医药首 ...

Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - By 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - Since 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Group 1: Fixed Income Market - The main economic indicators weakened in October, leading to expectations of interest rate cuts and reserve requirement ratio reductions to support the economy [7] - The three pillars supporting the economy are under pressure, with negative growth in infrastructure and real estate investments [7] - The central bank has indicated the need for counter-cyclical and cross-cyclical adjustments, suggesting that policy rate cuts and new tools may be key to economic support in the coming months [7] Group 2: Pharmaceutical Industry - The small nucleic acid drug market is expected to grow significantly, with a projected market size of approximately $62 billion in 2024 and $467 billion by 2033, reflecting a compound annual growth rate of 25% [12] - Alnylam Pharmaceuticals is a leader in the siRNA field, with strong commercialization performance and a revenue of $2.617 billion in the first three quarters of 2025, a 58% year-on-year increase [13] - The industry is characterized by a high degree of activity in business development transactions, with over $45 billion in cumulative transactions in the siRNA sector from 2018 to November 2025 [12] Group 3: Consumer Electronics - The 2025 "Double Eleven" shopping festival saw a total e-commerce sales of 1.695 trillion yuan, a year-on-year increase of 14.2%, with the home appliance sector showing resilience and growth [14][15] - Home appliances accounted for 266.8 billion yuan in sales during the event, representing a 38.2% increase year-on-year, indicating a shift towards smart and integrated appliances [15] - Companies like Haier, Midea, and TCL achieved significant sales milestones, with over 10 billion yuan in transactions during the festival [15] Group 4: Transportation Industry - The express delivery sector experienced record volumes during the "Double Eleven" period, with 13.938 billion packages collected, marking a 117.8% increase in daily average volume compared to regular operations [20] - The oil transportation market is expected to strengthen in December, with VLCC daily earnings reaching $124,000, the highest since Q2 2020, driven by increased demand from the Middle East and Brazil [22] - The logistics sector is benefiting from improved collaboration with e-commerce platforms, enhancing operational efficiency and supporting consumer demand [20] Group 5: Precious Metals - The precious metals market is poised for potential upward movement, with gold prices recently rebounding but not surpassing previous highs, influenced by the end of the U.S. government shutdown and upcoming economic data releases [36][38] - Gold and silver prices have shown recent increases, with gold reaching $4,071.10 per ounce and silver at $52.01 per ounce, reflecting market reactions to economic conditions [35] - The market is closely monitoring key upcoming economic reports, including non-farm payrolls and GDP revisions, which could impact precious metal prices [38]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is a long-term phenomenon, with external environmental changes having limited impact. In the first half of 2025, there were 72 License-out transactions, exceeding half of the total for 2024, with a total transaction amount 16% higher than in 2024. Notably, there were 16 transactions exceeding $1 billion each [2] - The small nucleic acid drug sector has seen significant breakthroughs, particularly in the treatment of chronic diseases such as hypertension and hyperlipidemia, with major collaborations and potential milestone payments indicating a robust commercial outlook [3] - The trend towards oral autoimmune drugs is gaining attention, with significant partnerships and clinical advancements in this area, highlighting the importance of oral formulations in autoimmune therapies [4] - Recent clinical data on long-acting insulin analogs shows promising weight loss results, with ongoing developments in combination therapies for metabolic diseases, indicating a growing market potential [5] - The CXO sector is gradually recovering, with an increase in License-out transactions serving as a vital funding source for biotech companies, leading to a resurgence in innovation and clinical development [6] - The 2025 national medical insurance negotiations and the commercial insurance innovative drug directory are crucial for companies involved, with a focus on orphan drugs and imported PD-1/L-1 products [7] Summary by Sections Industry Tracking - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a recent weekly decline of 1.20% and a monthly decline of 3.38%, ranking 25th among 31 industry indices [22][26] Industry Trends and Valuation - The pharmaceutical industry index currently has a PE ratio of 39.05, above the five-year historical average of 31.36, indicating a higher valuation compared to historical trends [48][50] Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical topics, including the growth of the blood products industry and the potential of GLP-1 drugs in chronic disease management [53] Important Policies and News - Recent regulations have been introduced to standardize clinical research and ensure drug traceability, which will impact the pharmaceutical landscape significantly [55][56]

Core Insights - The report highlights the significant advantages of ASIC over GPU in terms of cost-effectiveness and energy efficiency, marking a turning point for ASIC development [2][12] - The increasing penetration of AI is driving a surge in inference demand, expanding the market space for ASICs [3][12] - Domestic cloud providers are making strides in self-developed ASICs, indicating a strong demand in the Chinese AI cloud market [12][13] Summary by Sections ASIC vs. GPU - ASICs are specialized chips tightly coupled with downstream applications, focusing on specific needs like text and video inference, while GPUs are general-purpose chips covering a broader range of applications [2][12] - The energy efficiency of Google's TPU v5 is 1.46 times that of NVIDIA's H200, and Amazon's Trainium2 reduces training costs by 40% compared to GPU solutions [2][12] Market Growth and Demand - The global AI ASIC market is projected to reach $125 billion by 2028, with significant contributions from major clients [3][12] - The demand for inference computing is directly linked to throughput, with ChatGPT's weekly active users reaching 700 million by July 2025, driving the need for increased computational power [3][12] ASIC Design Services - ASIC design requires a high level of specialization, with major service providers like Broadcom and Marvell leading the market [3][12] - Broadcom's collaboration with Google on TPU has been pivotal, leveraging a comprehensive IP system and advanced packaging technologies [3][12] Domestic Developments - Leading Chinese cloud providers are achieving results in self-developed ASICs, with significant orders and advancements in technology [12][13] - The trends of PD separation and super nodes are emerging as key developments in the domestic ASIC landscape [12][13] Industry Outlook - The report anticipates a robust growth trajectory for the ASIC market, driven by increasing AI applications and domestic innovation [12][13]

Summary of Key Points from Conference Call Records Industry: Energy Storage Core Insights and Arguments - **Price Increase**: Energy storage cell prices have been rising continuously since June-July 2025, with average prices for 314/280Ah cells reaching 0.295 RMB/Wh. PCS prices have also increased by 0.005 RMB/W to 0.07 RMB/W, indicating a clear trend of price stabilization in the system end, which is expected to improve profitability across the industry [1][2]. - **Market Demand**: Major battery manufacturers are forecasting a shipment growth of 30-50% for 2026, significantly higher than the market's expectation of over 20% growth. This demand is driven by independent energy storage in China and strong overseas demand [1][2]. - **Profitability**: A surveyed 100MW/200MWh power station in Shandong can achieve annual peak-valley price arbitrage profits of 20 million RMB, doubling from 2023 levels. The market is becoming more optimistic, with investment expectations shifting positively [1]. Supply Side - **Capacity Utilization**: Leading battery manufacturers like CATL, EVE, and Haicheng are operating at full capacity, with significant year-on-year increases in capacity utilization for companies like Ruipu and AVIC [2]. Key Companies - **Haibo Technology**: Expected to see a significant increase in Q3 shipments to 9-10GWh, a 46% increase from the previous quarter. The company’s domestic net profit per unit is 0.02 RMB, while overseas is 0.2 RMB, indicating a tenfold difference [2]. - **EVE Energy**: Plans to expand its energy storage capacity to 80GWh in 2025, 120GWh in 2026, and 150GWh in 2027, with current capacity utilization nearing full [2]. Industry: Small Nucleic Acid Drugs Core Insights and Arguments - **Market Growth**: The global small nucleic acid drug market is projected to reach approximately $5.78 billion in 2024, surpassing $10 billion in 2025, and reaching $25 billion by 2030, with a CAGR of 19.5% [4]. - **Recent Collaborations**: Domestic siRNA leader, Wobang Pharmaceutical, has partnered with Novartis for cardiovascular product development, with a total package worth $5.36 billion [3]. Key Companies - **Yuekang Pharmaceutical**: Has established a leading R&D platform for nucleic acid drugs, with its first siRNA drug YKYY015 approved for clinical trials in China and the US [4]. - **Fuyuan Pharmaceutical**: Developing siRNA drugs targeting hyperlipidemia, with its core project FY101 entering Phase I clinical trials [5]. Industry: Solid-State Batteries Core Insights and Arguments - **Production Milestone**: EVE Energy's solid-state battery production line has been officially launched, with the "Longquan No. 2" all-solid-state battery successfully produced [6]. - **Market Potential**: The solid-state battery market is expected to exceed 100 billion RMB, with significant demand for core equipment and materials [6]. Key Companies - **EVE Energy**: Plans to produce nearly 500,000 battery cells annually after full production, with a focus on high-end applications such as humanoid robots and low-altitude aircraft [7]. Industry: Apple Foldable Devices Core Insights and Arguments - **Increased Production Estimates**: Apple has revised its foldable iPhone shipment estimates for 2026 and 2027 to 8-10 million and 20-25 million units, respectively [8]. - **Technological Innovations**: The new devices will utilize ultra-thin glass and liquid metal for hinges to enhance durability and reduce screen creasing [8]. Key Companies - **Yian Technology**: Reported to be the exclusive supplier of liquid metal hinge components for Apple [8]. Industry: Pharmaceutical Development Core Insights and Arguments - **New Drug Approvals**: Chenxin Pharmaceutical is advancing a new drug for drug-resistant tuberculosis, expected to apply for approval in 2025, with peak sales projected at 1-1.3 billion RMB [9][10]. Key Companies - **Baihua Pharmaceutical**: Focused on developing innovative drugs and enhancing its clinical research capabilities [14]. Industry: Photovoltaics Core Insights and Arguments - **Market Dynamics**: The price of polysilicon has increased, with mainstream prices reaching 55 RMB/kg for rod silicon and 49 RMB/kg for granular silicon [11]. - **Technological Advancements**: The company is investing in high-efficiency heterojunction solar cells and has achieved over 32% efficiency in laboratory tests for perovskite/heterojunction tandem cells [11]. Key Companies - **Baoxin Technology**: Actively developing high-efficiency heterojunction solar cells and expanding production bases [11]. Industry: Data Center Cooling Solutions Core Insights and Arguments - **Market Position**: Weilon Technology has supplied liquid cooling valves to major data centers, including Microsoft, with a projected revenue of $4 million in 2025 [12]. Key Companies - **Weilon Technology**: The only domestic supplier of valves to North American AIDC projects, leading the market by 1-2 years [12]. Risk Considerations - The information provided is for reference only, and the accuracy and completeness cannot be guaranteed. Investors should conduct their own research and make independent decisions [18].

Core Insights - The establishment of the second QFLP fund by Qiming Venture Partners in Kunshan, Jiangsu, marks a significant development in the cross-border investment landscape, following the first fund launched in Shanghai in 2011 [1][8] - QFLP serves as a crucial tool for international investors to access China's private equity market, facilitating the conversion of foreign currencies into RMB and bypassing complex approval processes [4][5] - The successful launch of the QFLP project in Kunshan reflects the city's strong industrial foundation, innovative ecosystem, and favorable regulatory environment, making it an attractive destination for international capital [9][11] QFLP Overview - QFLP (Qualified Foreign Limited Partner) allows foreign investors to invest in domestic equity investment funds after passing qualification reviews and foreign exchange regulations, providing multiple advantages such as flexible currency exchange and investment convenience [4][5] - The QFLP fund can channel investments into emerging sectors like renewable energy and AI, benefiting both foreign capital and local enterprises [4][5] Kunshan's Competitive Advantages - Kunshan is recognized for its robust industrial base, with an economic output exceeding 500 billion RMB, and is focusing on developing a new industrial system that includes core industries, AI, and green low-carbon initiatives [8][11] - The city has established itself as a financial reform pilot zone, offering innovative policies that facilitate cross-border investment, thus creating a "green channel" for QFLP fund establishment [11][19] - Efficient government services and a collaborative mechanism between Kunshan and Qiming Venture Partners have expedited the fund's establishment process, showcasing the city's commitment to fostering a conducive investment environment [15][19] Strategic Collaborations - The partnership between Qiming Venture Partners and Kunshan has been ongoing since 2021, with previous investments in technology companies and a focus on integrating international technological advancements into local industries [12][14] - The recent QFLP project signifies an upgrade in collaboration, with plans for further investments in early-stage and growth-stage companies in technology and medical innovation sectors [7][14] Future Implications - The launch of the QFLP project in Kunshan is seen as a new starting point, transitioning the city from merely attracting capital to leveraging capital to drive industrial growth, providing a model for other cities exploring similar financial and industrial integration strategies [20]

Group 1: A+H Listing Expansion - The Hong Kong stock market is experiencing a surge in listing applications, with 14 companies submitting applications between April 25 and 28, including industry leaders seeking A+H listings [1] - Three Squirrels aims to become the first A+H snack brand, reporting a projected revenue of 10.622 billion yuan and a net profit of 408 million yuan for 2024, with 70% of revenue coming from online channels [2] - JA Solar has submitted its application for an A+H listing, reporting a projected revenue of 70.121 billion yuan for 2024, but facing a net loss of 4.656 billion yuan due to asset impairment losses [3][4] - Seres has successfully turned a profit in 2024, with a revenue of 1.45176 billion yuan and a net profit of 5.946 billion yuan, driven by increased sales of electric vehicles [5][6] Group 2: Companies Transitioning to Hong Kong - Rebio Biotech has submitted its application to the Hong Kong Stock Exchange after previously attempting to list on the A-share market, reporting a net loss of 437.3 million yuan in 2023 [8][9] - Daji Group, which focuses on innovative radiation surgery solutions, has also shifted its listing application to Hong Kong after previously applying for the Sci-Tech Innovation Board [10][11] - Hongyeji has submitted its application to the Hong Kong Stock Exchange after previously attempting to list on the Shenzhen Stock Exchange, reporting revenues of approximately 1.228 billion yuan in 2022 [12]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry. Core Insights - The small nucleic acid field is experiencing significant advancements in patent strategies, particularly in the areas of chemical modifications and delivery technologies. Companies like Alnylam are leading the way in establishing a strong patent barrier through innovative approaches to RNA modifications and targeted delivery systems [4][24][25]. Summary by Sections Current Patent Landscape - The report outlines the current patent landscape in the small nucleic acid sector, highlighting key patents related to siRNA mechanisms and structural features. Early patents primarily cover siRNA mechanisms and typical structural characteristics, with companies like Alnylam acquiring exclusive licenses to build their patent barriers [8][9]. Challenges in Chemical Modification Searches - The report identifies challenges in searching for chemical modifications, including the diversity of modification descriptions and the lack of commercial databases supporting searches by chemical type. It emphasizes the need for standardized modification descriptions to facilitate better patent searches [22][27][32]. Breakthroughs in Domestic Small Nucleic Acid Design - The report discusses breakthroughs in domestic small nucleic acid design, focusing on the development of siRNA targeting validated genes. It emphasizes the importance of establishing "target patents" to protect against early entrants in the market [11][39]. Case Study: HSD17B13 - A case study on HSD17B13 highlights the active research and patenting efforts by companies like Regeneron and Alnylam in developing RNAi therapies targeting this gene. The report details the specific sequences and modifications involved in these patents [37][39][54]. Patent Search Workflow - The report outlines a comprehensive workflow for patent searches in the small nucleic acid field, including target name searches, sequence searches, and modification searches. This structured approach aims to streamline the identification of relevant patents and potential infringement risks [36][45][51].